RxDoctor Payments Data

Erin Macneill

Family · Norwood, MANPI 1134596778

Payments from drug & device makers

$2,123in general payments, 2019–2025

Across 47 payments — averaging $45.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inspire Medical Systems, Inc.$837
  • AstraZeneca$456
  • Sanofi$261
  • GSK$156
  • Verona Pharma, Inc.$112
  • Sanofi-aventis U.S. LLC$100
  • plus $200 from 4 others

What the payments were for

  • Travel & lodging$63230%
  • Food & beverage$1,27860%
  • Education$21310%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,123 in reported general payments places this provider in the 90th percentile of 2,320 family providers in Massachusetts.

See all family providers in Massachusetts

Medicare billing

Part B allowed, 2024
$23,412
Medicare patients
101
Services billed
248

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Fasenra PenBenralizumab54$304,553
TezspireTezepelumab-Ekko29$144,488
Dupixent PenDupilumab40$142,259
Trelegy ElliptaFluticasone/Umeclidin/Vilanter158$132,821
Spiriva RespimatTiotropium Bromide58$46,474
XolairOmalizumab23$41,977
Breztri AerosphereBudesonide/Glycopyr/Formoterol39$27,203
SymbicortBudesonide/Formoterol Fumarate65$19,930
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr17$10,410
Breo ElliptaFluticasone/Vilanterol18$9,579
DuleraMometasone/Formoterol14$7,409
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate30$6,563
Incruse ElliptaUmeclidinium Bromide12$4,131
Albuterol Sulfate HfaAlbuterol Sulfate79$2,824
Fluticasone-SalmeterolFluticasone Propion/Salmeterol15$2,646

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaTezspire, Breztri Aerosphere, Symbicort$456$191,622133 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta$156$156,941205 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,320 family providers in Massachusetts.

Other family in Norwood

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →